Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients

被引：751

作者：

Gyoerffy, Balazs ^{[1
,2
]}

Lanczky, Andras ^{[3
]}

Szallasi, Zoltan ^{[4
,5
]}

机构：

[1] Hungarian Acad Sci, Res Lab Pediat & Nephrol, Budapest, Hungary

[2] Inst Pathol, Lab Funct Genom, Berlin, Germany

[3] Semmelweis Univ, Dept Pathol 2, H-1083 Budapest, Hungary

[4] Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark

[5] Harvard Univ, Childrens Hosp, Sch Med, Boston, MA 02115 USA

来源：

关键词：

INDEPENDENT PROGNOSTIC-FACTOR; TELOMERASE REVERSE-TRANSCRIPTASE; FACTOR RECEPTOR EXPRESSION; CYCLE REGULATORY PROTEINS; CA-125; HALF-LIFE; POOR-PROGNOSIS; CLINICAL-RELEVANCE; GROWTH-FACTOR; C-MYC; REDUCED EXPRESSION;

D O I：

10.1530/ERC-11-0329

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The validation of prognostic biomarkers in large independent patient cohorts is a major bottleneck in ovarian cancer research. We implemented an online tool to assess the prognostic value of the expression levels of all microarray-quantified genes in ovarian cancer patients. First, a database was set up using gene expression data and survival information of 1287 ovarian cancer patients downloaded from Gene Expression Omnibus and The Cancer Genome Atlas (Affymetrix HG-U133A, HG-U133A 2.0, and HG-U133 Plus 2.0 microarrays). After quality control and normalization, only probes present on all three Affymetrix platforms were retained (n=22 277). To analyze the prognostic value of the selected gene, we divided the patients into two groups according to various quantile expressions of the gene. These groups were then compared using progression-free survival (n=1090) or overall survival (n=1287). A Kaplan-Meier survival plot was generated and significance was computed. The tool can be accessed online at www.kmplot.com/ovar. We used this integrative data analysis tool to validate the prognostic power of 37 biomarkers identified in the literature. Of these, CA125 (MUC16; P=3.7 x 10(-5), hazard ratio (HR) = 1.4), CDKN1B (P = 5.4 x 10(-5), HR=1.4), KLK6 (P=0.002, HR=0.79), IFNG (P=0.004, HR=0.81), P16 (P=0.02, HR=0.66), and BIRC5 (P=0.00017, HR=0.75) were associated with survival. The combination of several probe sets can further increase prediction efficiency. In summary, we developed a global online biomarker validation platform that mines all available microarray data to assess the prognostic power of 22 277 genes in 1287 ovarian cancer patients. We specifically used this tool to evaluate the effect of 37 previously published biomarkers on ovarian cancer prognosis. Endocrine-Related Cancer (2012) 19 197-208

引用

页码：197 / 208

页数：12

共 102 条

[1]

The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel [J].

Ahmed, Ahmed Ashour ;

Mills, Anthony D. ;

Ibrahim, Ashraf E. K. ;

Temple, Jillian ;

Blenkiron, Cherie ;

Vias, Maria ;

Massie, Charlie E. ;

Iyer, N. Gopalakrishna ;

McGeoch, Adam ;

Crawford, Robin ;

Nicke, Barbara ;

Downward, Julian ;

Swanton, Charles ;

Bell, Stephen D. ;

Earl, Helena M. ;

Laskey, Ronald A. ;

Caldas, Carlos ;

Brenton, James D. .

CANCER CELL, 2007, 12 (06) :514-527

[2]

Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer [J].

Baekelandt, M ;

Holm, R ;

Nesland, JM ;

Tropé, CG ;

Kristensen, GB .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) :3775-3781

[3]

Baekelandt M, 1999, CLIN CANCER RES, V5, P2848

[4]

Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer [J].

Bali, A ;

O'Brien, PM ;

Edwards, LS ;

Sutherland, RL ;

Hacker, NF ;

Henshall, SM .

CLINICAL CANCER RESEARCH, 2004, 10 (15) :5168-5177

[5]

Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer [J].

Barbieri, F ;

Lorenzi, P ;

Ragni, N ;

Schettini, G ;

Bruzzo, C ;

Pedullà, F ;

Alama, A .

ONCOLOGY, 2004, 66 (04) :310-315

[6]

Becker K, 2006, INT J ONCOL, V29, P889

[7]

Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy [J].

Bedrosian, Isabelle ;

Lee, Christine ;

Tucker, Susan L. ;

Palla, Shana L. ;

Lu, Karen ;

Keyomarsi, Khandan .

CLINICAL CANCER RESEARCH, 2007, 13 (16) :4800-4806

[8]

Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[9]

EPIDERMAL GROWTH-FACTOR RECEPTOR EXPRESSION IN NORMAL OVARIAN EPITHELIUM AND OVARIAN-CANCER .1. CORRELATION OF RECEPTOR EXPRESSION WITH PROGNOSTIC FACTORS IN PATIENTS WITH OVARIAN-CANCER [J].

BERCHUCK, A ;

RODRIGUEZ, GC ;

KAMEL, A ;

DODGE, RK ;

SOPER, JT ;

CLARKEPEARSON, DL ;

BAST, RC .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 164 (02) :669-674

[10]

Oncogenic pathway signatures in human cancers as a guide to targeted therapies [J].

Bild, AH ;

Yao, G ;

Chang, JT ;

Wang, QL ;

Potti, A ;

Chasse, D ;

Joshi, MB ;

Harpole, D ;

Lancaster, JM ;

Berchuck, A ;

Olson, JA ;

Marks, JR ;

Dressman, HK ;

West, M ;

Nevins, JR .

NATURE, 2006, 439 (7074) :353-357

← 1 2 3 4 5 6 7 8 9 10 →